MDSpire - Takeaway
From the Journals

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

Share

  • 1

    LITESPARK-022 study evaluated adjuvant pembrolizumab plus belzutifan.

  • 2

    Significant improvement in disease-free survival noted.

  • 3

    24-month survival rate: 80.7% for combination vs 73.7% for pembrolizumab alone.

  • 4

    Safety profile consistent with known drug profiles.

  • 5

    Longer-term follow-up needed for overall survival analysis.

Original Source(s)

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

  • by Jo Cavallo

  • March 31, 2026

Related Content

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer.

  • by

  • March 31, 2026

  • 3 min
It's Like PCR, But Better

Geoff Smith introduces the mcPCR method for methylated DNA analysis that is expanding the potential of epigenetics for disease detection